Summit Securities Group’s Bristol-Myers Squibb BMY Stock Holding History

Summit Securities Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,700	Closed	-$464K	–	893
2023 Q1	$464K	Hold	6,700	–	–	0.04%	145
2022 Q4	$482K	Hold	6,700	–	–	0.02%	246
2022 Q3	$476K	Buy	6,700 +4,000	+148%	+$290K	0.04%	259
2022 Q2	$208K	Sell	2,700 -300	-10%	-$22.8K	0.03%	294
2022 Q1	$219K	Sell	3,000 -63,200	-95%	-$4.24M	0.02%	366
2021 Q4	$4.13M	Buy	66,200 +65,538	+9,900%	+$3.84M	0.19%	92
2021 Q3	$3.92M	Sell	662 -308	-32%	-$20.3K	0.31%	80
2021 Q2	$6.48M	Buy	970 +270	+39%	+$17.6K	0.54%	35
2021 Q1	$4.42M	Buy	+700	New	+$43.6K	0.48%	38
2020 Q2	–	Sell	-1,100	Closed	-$6.13M	–	417
2020 Q1	$6.13M	Sell	1,100 -246	-18%	-$15K	1.08%	27
2019 Q4	$8.64M	Sell	1,346 -254	-16%	-$14.5K	0.65%	37
2019 Q3	$8.11M	Sell	1,600 -1,000	-38%	-$47K	0.72%	22
2019 Q2	$11.8M	Sell	2,600 -5,077	-66%	-$236K	1.37%	14
2019 Q1	$36.6M	Buy	+7,677	New	+$382K	6.69%	3
2017 Q4	–	Sell	-276	Closed	-$1.76M	–	183
2017 Q3	$1.76M	Buy	+276	New	+$16.1K	0.3%	40

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's BMY Position: Q1 2026 in Review

Summit Securities Group reduced its Bristol-Myers Squibb (BMY) stake by 96% in Q1 2026, selling an estimated $4.8M and leaving 3,134 shares worth $190K. The position accounts for 0.02% of the portfolio, ranked #231.

Summit Securities Group first reported a position in BMY in Q2 2013 and has held it in 45 quarters since. The position peaked at $22.6M in Q4 2019. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Summit Securities Group held 3,134 shares of Bristol-Myers Squibb worth $190K as of Q1 2026.
Summit Securities Group sold 82,290 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.8M.
Bristol-Myers Squibb made up 0.02% of Summit Securities Group's portfolio in Q1 2026, its #231 holding.
Summit Securities Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 45 quarters since.
Summit Securities Group's Bristol-Myers Squibb position peaked at $22.6M in Q4 2019.
2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.